

**Activity Outline**  
**Topics in Public Health: Sexually Transmitted Disease & Cervical Cancer Screening: What, When, & How**  
**January 17, 2020**  
**Webinar**

**Activity Coordinator:**

Ashlee Januszewicz (Ashlee.Januszewicz@fda.hhs.gov), Amy Ramanadham (Amy.Ramanadham@fda.hhs.gov),

**Series Description**

This series will educate PHS health professionals about topics that are pertinent to their roles within the various agencies within the Department of Health and Human Services and other Public Health Service agencies by presenting topics that directly relate to the HHS Strategic Plan, the Secretary's Strategic Initiatives, current topics for DHHS OPDIVs who utilize PHS health professionals, and/or other topics directly related to the advancement of public health.

**Lecture Description**

The information that will be presented will focus on the various types of sexually transmitted infections (STI's). A discussion of the signs and symptoms and long-term prognosis of undetected and not treated STI's. Another area that will be reviewed is the updated cervical cancer screening guidelines and the importance of implementation for the age appropriate at the specified time frames. This will cover the history of cervical cancer screening, the evidenced based guidelines, as well as the significance of the updates from the leading authorities.

**References**

- American Cancer Society [ACS]. (2018). <https://www.cancer.gov/about-cancer/understanding/statistics>
- American Cancer Society [ACS]. (2019). <http://www.cancer.org/cancer/cervical-cancer/about/key-statistics.html>
- American College of Obstetrics and Gynecology [ACOG], (2019). Practice advisory: Cervical cancer screening (update). Retrieved from <https://www.acog.org/Clinical-Guidance-and-Publications/Practice-Advisories/Practice-Advisory-Cervical-Cancer-Screening-Update>
- American Society for Colposcopy and Cervical Pathology. (2014). Updated consensus guidelines for managing abnormal cervical cancer screening tests and cancer precursors. Retrieved from <http://www.asccp.org/asccpguidelines>
- Asiedu, G.B., Radecki Breitkopf, C.& Breitkopf, D.M.(2014). Perceived risk of cervical cancer among low income women. Journal of Lower Genital Tract Disease, 18(4), 304-308. [h:p://dx.doi.org/10.1097/lgt](http://dx.doi.org/10.1097/lgt).

**Series Objectives**

- Describe scientific evidence supporting the HHS Initiatives, Surgeon General Priorities or any other public health concern
- Explain the multi-disciplinary approach in addressing public health issues
- Identify public health concerns.
- Identify ways Public Health Professionals can impact public health issues.

**Learning Objectives** After completion of this activity, the participant will be able to:

- Identify sexually transmitted infections and the various types.
- Identify the history of cervical cancer screening.
- Identify the connection of high-risk human papilloma virus in cervical cancer.
- Identify the age cervical cancer screening should start and the importance of age appropriate screening per 2012 and 2018 guidelines.

**Target Audience**

This activity is intended for physicians, pharmacists, nurses, and other public health medical professionals interested in learning more about the initiatives other advances in public health.

**Agenda**

**Lecture 1 January 17, 2020**

Time	Topic	Speaker
2:00 - 3:00 PM	Sexually Transmitted Disease & Cervical Cancer Screening: What, When, & How	Julia Shemek, WHNP-BC

## Continuing Education Accreditation



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

### CME

FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### CPE

This knowledge-based activity has been assigned ACPE Universal Activity Number JA0002895-0000-20-009-L04-P, and ACPE Universal Activity Number JA0002895-0000-20-009-L04-T for 1.00 contact hour(s).

### CNE

FDA Center for Drug Evaluation and Research designates this activity for 1.00 contact hour(s).

### CPH

Up to 1.00 CPH Recertification Credits may be earned at this event.

### Requirements for Receiving CE Credit

**Physicians, pharmacists, nurses, pharmacist techs, and those claiming non-physician CME:** participants must attest to their attendance and complete the final activity evaluation via the CE Portal ([ceportal.fda.gov](http://ceportal.fda.gov)). For multi-day activities, participants must attest to their attendance and complete the faculty evaluation each day. Final activity evaluations must be completed within two weeks after the activity - no exceptions.

Pharmacists will need their NABP e-profile ID number as well as their DOB in MMDD format in order to claim CE credit.

### Important Note regarding completion of evaluations and receiving credit

Attendees have 14 days from the last day of the activity to log in, complete the required evaluation(s) and attest to your attendance to claim credit. Physicians and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 10 weeks after the last session of the activity to obtain their CE credit.

### Disclosure

#### Faculty

- Shemek, Julia, WHNP-BC, WHNP-BC, US Public Health Service - nothing to disclose

#### Planning Committee

- Birch-Smith, Postelle, PharmD - nothing to disclose
- Brodhead, LeAnn, PharmD, Health Insurance Specialist, CMS - nothing to disclose
- CHIN, EDWARD, Medical Officer, DNDP - nothing to disclose
- Chan, Vicky, Team Leader, FDA - nothing to disclose
- Giroux, Virginia, MSN, FNP-BC, Associate Director for Accreditation, FDA/CDER/OEP/DLOD - nothing to disclose
- Januszewicz, Ashlee, Pharm.D, Compounding Incidents Team Leader, FDA/CDER/OC/OU DLC - nothing to disclose
- La, Thang, PharmD, MPH, Central Triage Unit Manager, FDA/CDER/OSE/RSS - nothing to disclose
- Lal, Renu, Pharm.D., Pharmacist, FDA - nothing to disclose
- Lucero, Karly, RN, DNP, MSN/eD, CCHP, Regional Field Medical Coordinator, DHS - nothing to disclose
- McClain, Rena, PharmD, CMS - nothing to disclose
- Nabavian, Sadaf, Senior Regulatory Project Manager, FDA - nothing to disclose
- Ramanadham, Amy, Senior Regulatory Research Officer, U.S. Food and Drug Administration - nothing to disclose

disclose

**CE Consultation and Accreditation Team**

- ▣ Bryant, Traci, M.A.T., CE Consultant, FDA/CDER/OEP/DLOD - nothing to disclose
- ▣ Giroux, Virginia, MSN, FNP-BC, Associate Director for Accreditation, FDA/CDER/OEP/DLOD - nothing to disclose
- ▣ Zawalick, Karen, CE Team Leader, FDA/CDER/OEP/DLOD - nothing to disclose

**Registration Fee and Refunds**

Registration is complimentary, therefore refunds are not applicable.